Fierce Biotech1d
Roche to house its CVRM research work at Harvard's new research campus
Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it ...
EMS11d
FDA approves clot-dissolving agent for treatment of acute ischemic stroke
TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...
Roche to open innovation center at new Harvard campus in Allston that could employ hundreds
Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise ...
Nasdaq3d
Genentech : FDA Accepts SBLA For Gazyva For Lupus Nephritis Treatment
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application or sBLA for ...
GEN - Genetic Engineering and Biotechnology News1d
Roche Genentech Innovation Center Boston Launched at Harvard’s Enterprise Research Campus
The hub has also been created to strengthen an existing relationship between Harvard and Roche that has been in place for over a decade.
Pharmabiz19h
Roche launches Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston
Roche, announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will further strengthen the long-standing partnership in areas such ...
The Manila Times1d
Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard's Enterprise Research Campus in Allston
Roche will be the first to join Harvard's Enterprise Research Campus in Allston, taking a suite in the first phase of the ...
MedPage Today on MSN5d
Tenecteplase No Longer Off-Label as Stroke Lytic
Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...